Literature DB >> 3582482

Melphalan concentration dependent plasma protein binding in healthy humans and rats.

N H Greig, D J Sweeney, S I Rapoport.   

Abstract

The binding of melphalan to plasma proteins from four healthy humans and from rats was measured by centrifugal ultrafiltration. Melphalan concentrations were determined by HPLC and by measuring 14C-melphalan activity. In whole blood, melphalan was distributed preferentially in plasma. However, a constant fraction, 37%, which was independent of the total melphalan concentration in whole blood, was present within the red blood cells. The binding of melphalan to plasma proteins from humans was less than that from rats. In both, however, the fraction bound was constant throughout the concentration range (0.1 to 9.0 microM) that is achieved during standard-dose melphalan therapy. Albumin was the primary binding protein. At concentrations equal to or in excess of 33 microM, which have been achieved during high-dose melphalan therapy, free plasma melphalan concentrations were no longer linearly related to total drug concentrations, and the plasma protein binding of melphalan in the human became concentration dependent. This occurred at concentrations of 70 microM in the rat. Scatchard analysis of the data indicated the presence of 2 groups of binding sites. Class I sites had 0.03 and 0.4 binding sites per albumin molecule in humans and rats, with respective association constants of 4.43 X 10(4) M-1 and 1.92 X 10(4) M-1. Class II sites had 5.18 and 2.60 binding sites per molecule, with respective association constants of 3.82 X 10(2) M-1 and 2.01 X 10(2) M-1.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582482     DOI: 10.1007/bf00542192

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

1.  EXPERIMENTS ON DETERMINATION OF MELPHALAN BY FLUORESCENCE. INTERACTION WITH PROTEIN AND VARIOUS SOLUTIONS.

Authors:  M A CHIRIGOS; J A MEAD
Journal:  Anal Biochem       Date:  1964-03       Impact factor: 3.365

2.  Multiple myeloma--intermittent combination chemotherapy compared to continuous therapy.

Authors:  R P George; J L Poth; D Gordon; S L Schrier
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

3.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

Authors:  B Fisher; P Carbone; S G Economou; R Frelick; A Glass; H Lerner; C Redmond; M Zelen; P Band; D L Katrych; N Wolmark; E R Fisher
Journal:  N Engl J Med       Date:  1975-01-16       Impact factor: 91.245

4.  Pharmacokinetics of high dose melphalan.

Authors:  M R Hersh; T M Ludden; J G Kuhn; W A Knight
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

5.  High-performance liquid chromatographic analysis of melphalan in plasma, brain and peripheral tissue by o-phthalaldehyde derivatization and fluorescence detection.

Authors:  D J Sweeney; N H Greig; S I Rapoport
Journal:  J Chromatogr       Date:  1985-05-03

6.  Degradation of melphalan in aqueous solutions--influence of human albumin binding.

Authors:  H Ehrsson; U Lönroth
Journal:  J Pharm Sci       Date:  1982-07       Impact factor: 3.534

7.  The protein binding of methotrexate by the serum of normal subjects.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

8.  Pharmacokinetics of the absorption, distribution, and elimination of melphalan in the dog.

Authors:  R L Furner; R K Brown; G Duncan
Journal:  Cancer Treat Rep       Date:  1977-12

9.  Effects of cancer and its treatments on plasma concentration of alpha 1-acid glycoprotein and propranolol binding.

Authors:  F P Abramson; J Jenkins; Y Ostchega
Journal:  Clin Pharmacol Ther       Date:  1982-11       Impact factor: 6.875

10.  Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.

Authors:  M A Cornbleet; T J McElwain; P J Kumar; J Filshie; P Selby; R L Carter; D W Hedley; M L Clark; J L Millar
Journal:  Br J Cancer       Date:  1983-09       Impact factor: 7.640

View more
  12 in total

Review 1.  Determinants of passive drug entry into the central nervous system.

Authors:  M D Habgood; D J Begley; N J Abbott
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

2.  The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.

Authors:  U Loos; E Musch; M Engel; J H Hartlapp; E Hügl; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

Authors:  Christa E Nath; Peter J Shaw; Judith Trotman; Lihua Zeng; Stephen B Duffull; Gareth Hegarty; Andrew J McLachlan; Howard Gurney; Ian Kerridge; Yiu Lam Kwan; Peter Presgrave; Campbell Tiley; Douglas Joshua; John Earl
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

4.  Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.

Authors:  Ryan S Turley; Andrew N Fontanella; James C Padussis; Hiroaki Toshimitsu; Yoshihiro Tokuhisa; Eugenia H Cho; Gabi Hanna; Georgia M Beasley; Christina K Augustine; Mark W Dewhirst; Douglas S Tyler
Journal:  Clin Cancer Res       Date:  2012-04-10       Impact factor: 12.531

7.  Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

Authors:  N H Greig; T T Soncrant; H U Shetty; S Momma; Q R Smith; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.

Authors:  S Y Lee; R S Meehan; D C Seldin; J M Sloan; K Quillen; A Shelton; D Brauneis; V Sanchorawala
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

9.  Renal clearance and protein binding of melphalan in patients with cancer.

Authors:  P A Reece; H S Hill; R M Green; R G Morris; B M Dale; D Kotasek; R E Sage
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration.

Authors:  N H Greig; S Genka; E M Daly; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.